17 Apr 2020 --- Lonza Group reported Q1 net sales of CHF1.6 billion (US$1.65 billion), which represents an increase of 7.4 percent compared to the previous year at a constant exchange rate (CER). Segment growth in both the Lonza Pharma Biotech & Nutrition (LPBN) and the Lonza Specialty Ingredients (LSI) segments helped bolster overall Group performance, the company highlights. In this first quarter, Lonza further states its facilities continue to “largely remain operational” in light of the COVID-19 outbreak, and its business will continue “as planned” with key strategic growth projects.
